Arthneeti
All Q1 FY27 results →
GP

Gland Pharma

Q1 FY27

Gland Pharma Q1 FY27 earnings call: Revenue & Margins

Q1 FY27 earnings call: what management said on revenue, margins and capex.

Price₹3,043
Market cap₹50.2K Cr
P/E43.8
Updated16 Oct 2026
Read4 min read

Gland Pharma Q1 FY27 key numbers

Revenue
U.S. revenues currently about USD 110-120 million, expected to grow faster than the market (3-4%) due to new product launches and operational efficiencies.

As stated in Gland Pharma's Q1 FY27 earnings call transcript · published 25 Aug 2026. Reported figures, not investment advice.

The short version

Gland Pharma targets a 15% CAGR over the next 4-5 years; new contracts could push growth closer to 20% annually. Gland Pharma expects revenue growth at a CAGR of approximately 20%-25% over the next 4 years.

From Gland Pharma's Q1 FY27 earnings-call transcript · updated 16 Oct 2026.

Revenue & Sales Performance

Good growth
  • Gland Pharma targets a 15% CAGR over the next 4-5 years; new contracts could push growth closer to 20% annually.
  • U.S. revenues currently about USD 110-120 million, expected to grow faster than the market (3-4%) due to new product launches and operational efficiencies.
  • Complex product portfolio contribution is expected to increase post FY29, potentially taking a larger share of U.S. business revenue.
  • CDMO business aims to comprise around 30% of consolidated revenues in the near term, with higher margins than traditional IP-led business.
  • Bag line and ophthalmic products capacity expansions pending FDA approvals may accelerate growth beyond 15% in the current fiscal year.

2 more points from Gland Pharma's call on revenue

Create a free account to keep reading this call

Profitability & Margins

See what Gland Pharma said on profitability & margins — free account, 30 seconds.

Capital Expenditure Plans

Capex planned
  • Ongoing execution of a recently announced INR 2,000 crores capital expenditure program.
  • Q1 FY27 capex of INR 1,132 million towards capacity expansion, capability enhancements, infrastructure additions supporting CDMO and fill/finish platforms.
  • Immediate INR 165 crores capex for installing an isolator line in oncology plant (to be installed by January).
  • Capex towards vial, ophthalmic, BFS lines, and liposome products at India sites on track.
  • Capacity expansion projects approved and prioritized to meet growing CDMO collaboration demand.
  • Growth capex at Cenexi for adding a new block underway.
  • Neuland collaboration: capex for building an API block has started.

2 more points from Gland Pharma's call on capex

Create a free account to keep reading this call

Fundraising & Capital Structure

See what Gland Pharma said on fundraising & capital structure — free account, 30 seconds.

Order Book & Pipeline

  • Current order book size mentioned is around INR600 crore to INR700 crore, expected to increase further.
  • New contracts recently signed will contribute about 12% to current revenue, supporting a 20% growth over the next 4 years.
  • The company is actively working on both brownfield and greenfield expansions to support volume growth.
  • There is ongoing negotiation/discussion with partners for additional contracts, expected to provide more clarity on growth and order book by next quarter.
  • CDMO business currently contributes about 50% of revenue, with a near-term target to reach 30% on a consolidated basis.

2 more points from Gland Pharma's call on order book

Create a free account to keep reading this call

What the Q1 FY27 call signalled

4 of 4 strong

RevenueGood growth
MarginMargins up
CapexCapex planned
FundraiseFundraise planned

Gland Pharma — Quarterly revenue & net profit

Revenue Net profit
Dec 2024Q3 FY25
Mar 2025Q4 FY25
Jun 2025Q1 FY26
Sep 2025Q2 FY26
Dec 2025Q3 FY26
Mar 2026Q4 FY26

Q1 FY27 figures are not in this chart yet. Latest shown: Mar 2026 (Q4 FY26). The Q1 FY27 numbers from the filing are in the analysis on this page.

Reported quarterly figures (₹ Cr). Latest (Q4 FY26): revenue ₹1.7K Cr, net profit ₹367 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.

Full financials →

Continue your research

What Gland Pharma Ltd's management said in earlier quarters

Others in Pharmaceuticals & Biotechnology this season

  • KRM Ayurveda (Q1 FY27)

    Total income for Q1 FY27: ₹3,286.55 Lakhs, +32.4% YoY . Key investor presentation takeaways from KRM Ayurveda Ltd's Q1 FY27 investor presentation — and how it r

  • Balaxi Pharma (Q1 FY27)

    Q1 FY27 Revenue: ₹80.68 crore, up 14.1% YoY from ₹70.74 crore in Q1 FY26 (Page 20). Key investor presentation takeaways from Balaxi Pharma's Q1 FY27 investor pr

  • Sanjiv.Parant. (Q1 FY27)

    Q1 FY27 consolidated revenue from operations: ₹238.39 Mn, up 33.8% YoY from ₹178.92 Mn in Q1 FY26 (Page 25). Key investor presentation takeaways from Sanjivani

  • Natural Capsules (Q1 FY27)

    Revenue from Operations for Q1FY27: ₹48.71 crore . Key investor presentation takeaways from Natural Capsules Ltd's Q1 FY27 investor presentation — and how it ra

Compare:vs Sun Pharma.Inds.vs Divi's Lab.vs Torrent Pharma.

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →

Arthneeti Pro · Annual

Gland Pharma and 15K+ more earnings calls,
for less than your morning chai

a day

Every earnings call, ranking and concall Q&A across all four results seasons.

Secure Razorpay payment · instant access

Frequently Asked Questions

What were Gland Pharma Q1 FY27 results?

Gland Pharma targets a 15% CAGR over the next 4-5 years; new contracts could push growth closer to 20% annually. Gland Pharma expects revenue growth at a CAGR of approximately 20%-25% over the next 4 years.

What is Gland Pharma share price analysis?

Gland Pharma currently shows a moderate growth signal based on ranking data. The stock trades at a P/E of 43.8 with a market cap of ₹50,219 Cr. Investors should review the full earnings analysis for detailed insights.

Is Gland Pharma planning capital expenditure?

Ongoing execution of a recently announced INR 2,000 crores capital expenditure program.

Keep Gland Pharma on your radar — track it to get its next earnings analysis in your feed.

This analysis is AI-generated based on publicly available earnings data and the company's earnings call transcript. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.